Quebec City in 1994, Montreal in 2001, and Toronto in 2007!
Quebec City in 1994, Montreal in 2001 and Toronto in 2007!
TORONTO, CANADA, July 26, 2007-Over the past fourteen years Anapharm has established itself as a world class provider of clinical and bioanalytical services to international sponsors and offers strategically located operations in five Canadian cities. Most recently, we opened a 160-bed clinical facility in Toronto, Canada.
Toronto site features:
- Modern, efficient facilities;
- Over 40,000 sq ft, on the 6th floor with ample natural light and park views;
- Clinical site comprised of 4 spacious clinical units with a total capacity of 160 beds;
- Units can be combined in order to conduct larger studies;
- The clinic offers full clinical services and on-site Quality Assurance support. Project Management services continue to be offered at the same level of excellence as at our Quebec and Montreal sites. One of our bioanalytical sites is located nearby in Richmond Hill.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
